BioXcel Therapeutics, a clinical-stage biopharmaceutical company, has achieved an important milestone in its investigator-sponsored Phase 2 relapsed pancreatic cancer trial. The firm announced the completion of patient enrollment in a critical safety portion of the study, proposing a potential new treatment option for an aggressive form of cancer. The therapy trial involves BioXcel’s BXCL701 in combination with Merck’s KEYTRUDA.
Phase 2 of this trial was designed to assess the safety and tolerability of the BXCL701 and KEYTRUDA combination. The patients enrolled for the trial are those who have not responded to standard of care treatments. Pancreatic cancer is notoriously resistant to most traditional cancer treatments. The combination therapy approach is a promising option, as preclinical animal model data has shown that BXCL701 can enhance the anti-tumor effects of immune checkpoint inhibitors like KEYTRUDA.
The completion of patient enrollment marks the transition to the next significant stage of the study. The human proof of concept portion of the trial is expected to commence in the first half of 2024. Georgetown Lombardi Comprehensive Cancer Center is leading the process as the investigator for the study.
The broader scope of the trial aims to provide a significant expansion of actionable data, which will help determine the efficacy of the combination therapy option. The trial’s successful completion would represent a potentially notable shift in the treatment of relapsed pancreatic cancer.
This trial is among a series of investigational studies sponsored by BioXcel to accelerate the development of novel oncology therapies. However, it’s worth noting that detailed outcomes and insights from the safety portion of the trial have yet to be released and would form an integral part of the subsequent stages of the trial.
The final results of the trial, including potential effects on survival rates and any adverse reactions, will be eagerly awaited by both the medical community and those affected by pancreatic cancer.-END-
Comments